Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
BURNABY, British Columbia, April 28, 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference in Toronto, Canada on Tuesday, May 2, 2017 at 11:00 am ET.
A live audio webcast of the presentation will be available on the investors section of Xenon's website at www.xenon-pharma.com and will be available for replay following the event.
About Xenon Pharmaceuticals Inc.
Xenon is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy. For more information, please visit www.xenon-pharma.com.
Investor/Media Contact: Jodi Regts Senior Director, Corporate Affairs Xenon Pharmaceuticals Inc. Phone: 604.484.3353 Email: [email protected]
